Robert J. Bitterman, Chairman, President, and CEO of Phio Pharmaceuticals Corp., filed a Form 4 on November 10, 2026, disclosing a purchase of 25,000 shares of common stock on November 9, 2026.

Key Highlights

  • Transaction date: November 9, 2026, with the form filed November 10, 2026.
  • Shares acquired: 25,000 shares of Common Stock, $0.0001 par value, coded as a purchase (P).
  • Price per share: $0.82.
  • Post-transaction beneficial ownership: 789,871 shares, held directly.
  • Ownership note: According to the filing, the 789,871 shares include shares of common stock underlying unvested restricted stock units.
  • Reporting person role: Bitterman is identified as both a Director and an Officer, with the title Chairman, Pres. & CEO.

Bitterman's November 2026 Open-Market Purchase at Phio Pharmaceuticals

According to the filing, Robert J. Bitterman, who serves as Chairman, President, and Chief Executive Officer of Phio Pharmaceuticals Corp. (NASDAQ:PHIO), acquired 25,000 shares of the company's Common Stock, $0.0001 par value, on November 9, 2026. The transaction was recorded under code "P," indicating an open-market purchase, at a price of $0.82 per share. No Rule 10b5-1 plan designation was indicated for this transaction.

Following the reported transaction, the filing states that Bitterman beneficially owns 789,871 shares directly. The filing includes a footnote noting that this total includes shares of common stock underlying unvested restricted stock units. No derivative securities transactions were reported in Table II of the filing.

The form was signed by Lisa C. Carson as attorney-in-fact on November 10, 2026, and was filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. Bitterman's address of record is listed as c/o Phio Pharmaceuticals Corp., 411 Swedeland Rd., Ste 23-1080, King of Prussia, Pennsylvania 19406.

What Was Disclosed

Phio Pharmaceuticals Corp.'s Chairman, President, and CEO Robert J. Bitterman disclosed an open-market purchase of 25,000 shares of common stock at $0.82 per share on November 9, 2026, bringing his reported direct beneficial ownership to 789,871 shares, including shares underlying unvested restricted stock units.